Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals Inc. is projected to experience significant revenue growth, with Khindivi associated revenues anticipated to increase from $3 million in 2025 to a peak of $28 million by 2030. The company's strategic adjustments, which include raising the probability of Khindivi's launch to 100% and adjusting its expected launch date to June 2025, demonstrate confidence in its commercial execution capabilities. Additionally, the expectation of increased market penetration, from 40% to 60%, further supports a positive outlook on the company's financial trajectory moving forward, particularly in 2025 as a potential inflection point for revenue.

Bears say

Eton Pharmaceuticals Inc. operates in a niche market with products that target rare diseases, but its reliance on a limited product portfolio may pose significant risks to future growth and profitability. The company's valuation assumptions, including an 11% discount rate and a 2% terminal growth rate, suggest a conservative outlook on its long-term earnings potential. Despite a slight upward adjustment in the price target, the financial metrics underline a fundamental concern regarding Eton’s ability to sustainably increase shareholder value in the face of market uncertainties.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.